Skip to main content
. 2017 Aug 30;19(10):772–780. doi: 10.1016/j.neo.2017.07.009

Figure 6.

Figure 6

Combinations of bortezomib or carfilzomib with ONC201 have a synergistic anti-myeloma effect. The myeloma cell line ARP-1 was treated with a combination of ONC201 with either bortezomib (A) or carfilzomib (B) for 48 hours to evaluate their cell viabilities. Upper tables show a combination of ONC201 with bortezomib (BTZ) or carfilzomib (CFZ), and lower panels show the antagonism or synergism of the combinations. (C) Myeloma cells ARP-1 and RPMI8226 were cultured without (0) or with 2 μM of ONC201 (ONC) or 10 nM of bortezomib (BTZ) single or in a combination for 24 hours, and the cultured cells were then subjected to Western blot analysis. Shown are the levels of Bim proteins, cleaved (c) PARP, and GAPDH proteins in the tested ARP-1 or RPMI8226 cells. Results shown are representative of three to five independent experiments. (D) A depiction of the signaling mechanism for induction of apoptosis in myeloma cells by combination of ONC201 and bortezomib (BTZ).